|
|
|
MIRA INFORM REPORT
|
Report No. : |
515969 |
|
Report Date : |
26.06.2018 |
IDENTIFICATION DETAILS
|
Name : |
ZOLL MEDICAL CORPORATION |
|
|
|
|
Registered Office : |
269 Mill Road, Chelmsford, MA
01824 USA |
|
|
|
|
Country : |
United States |
|
|
|
|
Date of Incorporation : |
09.04.1980 |
|
|
|
|
Legal Form : |
Domestic Profit Corporation |
|
|
|
|
Line of Business : |
Subject Develops and Markets Medical Devices. |
|
|
|
|
No. of Employees : |
4000 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
A+ |
|
Credit Rating |
Explanation |
Rating Comments |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Exist |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (31.12.2017) |
Current Rating (01.04.2018) |
|
United States |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
UNITED STATES - ECONOMIC OVERVIEW
The US has the most technologically powerful economy in the world, with a per capita GDP of $59,500. US firms are at or near the forefront in technological advances, especially in computers, pharmaceuticals, and medical, aerospace, and military equipment; however, their advantage has narrowed since the end of World War II. Based on a comparison of GDP measured at purchasing power parity conversion rates, the US economy in 2014, having stood as the largest in the world for more than a century, slipped into second place behind China, which has more than tripled the US growth rate for each year of the past four decades.
In the US, private individuals and business firms make most of the decisions, and the federal and state governments buy needed goods and services predominantly in the private marketplace. US business firms enjoy greater flexibility than their counterparts in Western Europe and Japan in decisions to expand capital plant, to lay off surplus workers, and to develop new products. At the same time, businesses face higher barriers to enter their rivals' home markets than foreign firms face entering US markets.
Long-term problems for the US include stagnation of wages for lower-income families, inadequate investment in deteriorating infrastructure, rapidly rising medical and pension costs of an aging population, energy shortages, and sizable current account and budget deficits.
The onrush of technology has been a driving factor in the gradual development of a "two-tier" labor market in which those at the bottom lack the education and the professional/technical skills of those at the top and, more and more, fail to get comparable pay raises, health insurance coverage, and other benefits. But the globalization of trade, and especially the rise of low-wage producers such as China, has put additional downward pressure on wages and upward pressure on the return to capital. Since 1975, practically all the gains in household income have gone to the top 20% of households. Since 1996, dividends and capital gains have grown faster than wages or any other category of after-tax income.
Imported oil accounts for more than 50% of US consumption and oil has a major impact on the overall health of the economy. Crude oil prices doubled between 2001 and 2006, the year home prices peaked; higher gasoline prices ate into consumers' budgets and many individuals fell behind in their mortgage payments. Oil prices climbed another 50% between 2006 and 2008, and bank foreclosures more than doubled in the same period. Besides dampening the housing market, soaring oil prices caused a drop in the value of the dollar and a deterioration in the US merchandise trade deficit, which peaked at $840 billion in 2008. Because the US economy is energy-intensive, falling oil prices since 2013 have alleviated many of the problems the earlier increases had created.
The sub-prime mortgage crisis, falling home prices, investment bank failures, tight credit, and the global economic downturn pushed the US into a recession by mid-2008. GDP contracted until the third quarter of 2009, the deepest and longest downturn since the Great Depression. To help stabilize financial markets, the US Congress established a $700 billion Troubled Asset Relief Program (TARP) in October 2008. The government used some of these funds to purchase equity in US banks and industrial corporations, much of which had been returned to the government by early 2011. In January 2009, Congress passed and former President Barack OBAMA signed a bill providing an additional $787 billion fiscal stimulus to be used over 10 years - two-thirds on additional spending and one-third on tax cuts - to create jobs and to help the economy recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP. In 2012, the Federal Government reduced the growth of spending and the deficit shrank to 7.6% of GDP. US revenues from taxes and other sources are lower, as a percentage of GDP, than those of most other countries.
Wars in Iraq and Afghanistan required major shifts in national resources from civilian to military purposes and contributed to the growth of the budget deficit and public debt. Through FY 2018, the direct costs of the wars will have totaled more than $1.9 trillion, according to US Government figures.
In March 2010, former President OBAMA signed into law the Patient Protection and Affordable Care Act (ACA), a health insurance reform that was designed to extend coverage to an additional 32 million Americans by 2016, through private health insurance for the general population and Medicaid for the impoverished. Total spending on healthcare - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010.
In July 2010, the former president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act, a law designed to promote financial stability by protecting consumers from financial abuses, ending taxpayer bailouts of financial firms, dealing with troubled banks that are "too big to fail," and improving accountability and transparency in the financial system - in particular, by requiring certain financial derivatives to be traded in markets that are subject to government regulation and oversight.
In December 2012, the Federal Reserve Board (Fed) announced plans to purchase $85 billion per month of mortgage-backed and Treasury securities in an effort to hold down long-term interest rates, and to keep short-term rates near zero until unemployment dropped below 6.5% or inflation rose above 2.5%. The Fed ended its purchases during the summer of 2014, after the unemployment rate dropped to 6.2%, inflation stood at 1.7%, and public debt fell below 74% of GDP. In December 2015, the Fed raised its target for the benchmark federal funds rate by 0.25%, the first increase since the recession began. With continued low growth, the Fed opted to raise rates several times since then, and in December 2017, the target rate stood at 1.5%.
In December 2017, Congress passed and President Donald TRUMP signed the Tax Cuts and Jobs Act, which, among its various provisions, reduces the corporate tax rate from 35% to 21%; lowers the individual tax rate for those with the highest incomes from 39.6% to 37%, and by lesser percentages for those at lower income levels; changes many deductions and credits used to calculate taxable income; and eliminates in 2019 the penalty imposed on taxpayers who do not obtain the minimum amount of health insurance required under the ACA. The new taxes took effect on 1 January 2018; the tax cut for corporations are permanent, but those for individuals are scheduled to expire after 2025. The Joint Committee on Taxation (JCT) under the Congressional Budget Office estimates that the new law will reduce tax revenues and increase the federal deficit by about $1.45 trillion over the 2018-2027 period. This amount would decline if economic growth were to exceed the JCT’s estimate.
|
Source
: CIA |
STATUTORY
INFORMATION
|
|
|
Legal
Name: |
ZOLL MEDICAL CORPORATION |
|
Trade
Name: |
ZOLL |
|
ID: |
042711626 / Old ID Number: 000161345 |
|
Date
Created: |
1980 |
|
Date
Incorporated: |
09-04-1980 |
|
Legal
Address: |
269 Mill Road, Chelmsford, MA 01824 USA |
|
Operative
Address: |
84 State Street Boston, MA 02109 USA |
|
Telephone:
|
978824-4105 |
|
Fax: |
978-421-0025 |
|
Legal
Form: |
Domestic Profit Corporation |
|
Email: |
N/A |
|
Registered
in: |
Massachusetts |
|
Website:
|
www.zoll.com |
|
Contact: |
Mr. Jonathan A. Rennert, Chief
Executive Officer |
|
Staff:
|
4000 |
|
Activity: |
Medical Equipment & Supplies
Manufacturing |
|
|
|
|
Banks: |
U.S. BANK EQUIPMENT FINANCE, A DIVISION
OF U.S. BANK NATIONAL ASSOCIATION 1310 MADRID STREET MARSHALL MN 56258 |
|
|
|
|
History: |
The company was founded in 1980
and is based in Chelmsford, Massachusetts. ZOLL Medical Corporation is a
subsidiary of Asahi Kasei Corporation. The name was changed from: ZMI
CORPORATION on 01-29-1992 The name was changed from: ROSS
RESEARCH, INC. on 02-02-1984 Merged with ZMD CORPORATION
(DE) (Note: Entity is not registered in Massachusetts) on 11-20-2003 Merged with ASCLEPIUS
SUBSIDIARY CORPORATION on 04-26-2012 |
|
|
|
|
Key
Develeopments: |
|
|
|
ZOLL Medical Corporation Key Developments InterSystems Corporation and Zoll Medical Corporation Introduce New
Endoscopy Integration Capabilities May 29 18 InterSystems Corporation announced
a strategic collaboration with resuscitation and acute care provider ZOLL®
Medical Corporation, to improve the bidirectional exchange of patient health
information (PHI) between EMS providers, physicians, and emergency
departments, accelerating holistic and high-quality patient care delivery.
Through the implementation of InterSystems HealthShare, ZOLL created the ZOLL
Care Exchange to change how EMS providers communicate with hospitals and
health care providers. The ZOLL Care Exchange will also improve EMS quality
and reimbursement efficiency by providing more timely and complete updates on
patient outcomes and diagnoses. Both ZOLL and InterSystems will be available
at the annual HIMSS18 conference in Las Vegas, March 5 – 9, at InterSystems
Booth #4444 to discuss the partnership in greater detail and demonstrate the
solution. ZOLL will also be demonstrating the ZOLL Care Exchange using a
“Heart Attack” use case in the HIMSS18 Interoperability Showcase. ZOLL Medical Corporation Wins Singapore's Save-A-Life Initiative to
Install 5,000 AED Plus Units in Public Housing May 3 18 ZOLL Medical Corporation
announced that it has been awarded the Singapore Save-A-Life (SAL)
initiative's contract and is currently installing 5,000 AED Plus units in
public housing apartments across Singapore. The aim of the SAL initiative is
to enhance community first response to sudden cardiac arrest (SCA) outside of
hospitals. All 5,000 AED Plus units are expected to be deployed nationwide by
May 2019, with one AED installed for every two housing blocks at the lift
lobbies in public housing estates. ZOLL deployed about 500 AED Plus units
during the pilot project of the SAL initiative, which was first introduced in
2015. ZOLL Medical Corporation Announces Results from the Vest Prevention of
Early Sudden Death Trial Mar 10 18 ZOLL Medical Corporation
announced the results from the Vest Prevention of Early Sudden Death Trial
(VEST). The study demonstrated that use of the LifeVest® wearable
cardioverter defibrillator (WCD) reduced total mortality by 36% in the first
90 days following a heart attack for patients with a reduced heart function.
Results were presented as a Late-Breaking Clinical Trial at the American
College of Cardiology's 67th Annual Scientific Session in Orlando, Florida.
The VEST Trial studied use of the LifeVest WCD for patients who had recently
suffered a heart attack (clinically known as a myocardial infarction or
"MI") and had a reduced heart function (defined as a low-ejection
fraction or "EF" of 35% or less). The trial enrolled 2,302 adult
low-EF, post-MI patients, with or without revascularization (such as a stent
placement or bypass procedure) across 108 trial sites in four countries.
Patients were randomized to receive the LifeVest WCD and guideline directed
medical therapy (GDMT) or GDMT alone for 90 days. The 2017 American Heart
Association (AHA)/American College of Cardiology (ACC)/Heart Rhythm Society
(HRS) Guideline for Management of Patients with Ventricular Arrhythmias and
the Prevention of Sudden Cardiac Death include recommended use of the WCD for
a wide range of patients, including those who have a low EF following a heart
attack or new diagnosis of heart failure. |
|
|
|
PRINCIPAL
ACTIVITY
|
|
|
|
ZOLL Medical
Corporation develops and markets medical devices. |
|
Products/Services
description: |
Medical equipment |
|
Brands: |
SORENSEN, LIFE COR, SMART
ALARMS, SMARTVIEW, POWERCHARGER, WCD. |
|
Sales
are: |
Wholesale and retail. |
|
Clients: |
The Company offers solutions
for EMS, Hospitals, Public Safety, Alternate Care, Military, and
Government/Homeland Security. COMSA SEGURIDAD INTEGRAL SA DE CV Mexico INGENIERIA Y SISTEMAS ELECTROMEDICOSSA DE
CV Mexico |
|
Suppliers: |
MEDICO ELECTRODES LTD. UK A 123 SYSTEMS(CHINA)MATERIALS
CO. China Fabricators International Ltd. Hong Kong |
|
Operations
area: |
Asia Pacific, Australia ,
Brazil , Canada , China , Eastern Europe, Europe, Middle
East and Africa, France, Germany, India, Italy, Japan, Latin America, Middle
East and Africa, Netherlands, New Zealand, Russia, Taiwan, Thailand, Spain,
United Kingdom |
|
The
company imports from |
Asia, Europe |
|
The
company exports to |
Asia Pacific, Australia ,
Brazil , Canada , China , Eastern Europe, Europe,
Middle East and Africa, France, Germany, India, Italy, Japan, Latin America,
Middle East and Africa, Netherlands, New Zealand, Russia, Taiwan, Thailand,
Spain, United Kingdom |
|
The
subject employs |
4000 EMPLOYEES. |
|
Payments:
|
Regular |
|
|
|
LOCATION
|
|
|
Headquarters
: |
269 MILL ROAD, CHELMSFORD, MA
01824 USA |
|
Branches: |
No branch records |
|
Related
Companies: |
Eastern Europe Julia Gromyko, Distributor Manager
+ 79 0 35 84 0454 Mobile + 74 9 55 10 6133 Fax email: jgromyko@zoll.com Europe, Middle East and Africa Rob Engelkes, Director
Distributor Operations +31 481 36 64 10 Telephone +31 481 36 64 11 Fax +31 653 83 41 41 Mobile email: rengelkes@zoll.com ZOLL Medical France Patrice Blechet, Managing
Director Parc d’Affaires Parkile 164 Avenue Joseph Kessel 78960 Voisins le Bretonneux France +33 1 3057 7040 Telephone +33 1 3057 0285 Fax email:pblechet@zoll.com| website: www.zoll.fr ZOLL Medical Deutschland GmbH Alexander Aigner, Managing
Director Emil-Hoffmann Str. 13 50996 Cologne Germany + 49 2236 87 87 - 0 Telephone + 49 2236 87 87 - 77 Fax email: info@zollmedical.de website: www.zoll.com/de |
|
|
|
GROUP
STRUCTURE AND SUBSIDIARY COMPANIES
|
|
|
Listed at the stock exchange: |
NO |
|
Capital: |
NA |
|
Shareholders: |
This company operates as a
subsidiary of: Asahi Kasei Corporation Chiyoda, Tokyo, Tokio, Japón |
|
Management:
|
PRESIDENT A ERNEST WHITON 269 MILL ROAD CHELMSFORD, MA
01824 USA TREASURER JOHN P BERGERON 269 MILL ROAD CHELMSFORD, MA
01824 USA SECRETARY AARON GROSSMAN 269 MILL ROAD CHELMSFORD, MA
01824 USA VICE PRESIDENT JOHN P BERGERON 269 MILL ROAD CHELMSFORD, MA 01824
USA DIRECTOR DAICHI ARIMA 269 MILL ROAD CHELMSFORD, MA
01824 USA |
|
|
|
FINANCIAL
INFORMATION
|
|
|
|
The company does not make its financial statements public. The
following information has been provided by private sources: |
|
|
|
|
USD
2017 |
|
|
Estimated
Net Assets |
183
000 000 |
|
Cash
flow |
Normal |
|
|
|
LEGAL
FILINGS
|
|
|
|
|
|
PATENTS |
System for assisting rescuers
in performing cardio-pulmonary resuscitation (CPR) on a patient Patent number: 9682009 Type: Grant Filed: June 10, 2016 Date of Patent: June 20, 2017 Assignee: ZOLL MEDICAL
CORPORATION Inventors: Ziad F. Elghazzawi,
Jing Pan System and method for adapting
alarms in a wearable medical device Patent number: 9684767 Type: Grant Filed: July 18, 2016 Date of Patent: June 20, 2017 Assignee: ZOLL Medical
Corporation Inventors: Thomas E. Kaib,
Shane S. Volpe, John G. Clark, Ryan D. Macel, Phillip Hier Amsler Medical monitoring and
treatment device with external pacing Patent number: 9675804 Type: Grant Filed: March 24, 2016 Date of Patent: June 13, 2017 Assignee: ZOLL MEDICAL
CORPORATION Inventors: Jason T. Whiting,
Thomas E. Kaib, Rachel H. Carlson, Gregory R. Frank EMS decision support interface,
event history, and related tools Patent number: 9658756 Type: Grant Filed: January 9, 2014 Date of Patent: May 23, 2017 Assignee: ZOLL Medical
Corporation Inventors: Gary A. Freeman,
Annemarie Elizabeth Silver |
|
|
|
|
GOVERNMENT
CONTRACTS |
No legal records found. |
|
|
|
|
CASES |
Saunders v. Zoll Medical Corporation
et al Filed: March 5, 2018 as
1:2018cv00959 Plaintiff: Barbara Saunders Defendant: Zoll Medical
Corporation , Chuansheng Jonathan Wu , Southeastern Lung Care, PC and others Cause Of Action: Petition for
Removal- Product Liability Court: Eleventh Circuit ›
Georgia › Georgia Northern District Court Type: Torts - Injury › Personal
Injury: Health Care FALLON v. ZOLL MEDICAL
CORPORATION Filed: May 9, 2018 as
3:2018cv09011 Plaintiff: MICHAEL FALLON Defendant: ZOLL MEDICAL
CORPORATION Cause Of Action: Notice of
Removal Court: Third Circuit › New
Jersey › New Jersey District Court Type: Civil Rights › Other
Civil Rights Geraghty v. Zoll Medical
Corporation et al Filed: July 28, 2016 as
1:2016cv07656 Plaintiff: Bridget N Geraghty Defendant: Zoll Medical
Corporation, Zoll LLC, Zoll Data Systems, Inc. and others Cause Of Action: - Tort
Negligence Court: Seventh Circuit ›
Illinois › Illinois Northern District Court Type: Torts - Injury › Other
Personal Injury Lantigua v. Zoll Medical Corporation
et al Filed: July 22, 2016 as
1:2016cv11516 Plaintiff: Dewil Lantigua Defendant: Zoll Medical
Corporation , Technical Needs North, Inc. Cause Of Action: Notice of
Removal Court: First Circuit ›
Massachusetts › Massachusetts District Court Type: Other Statutes Laster v. Zoll Medical
Corporation Filed: June 23, 2014 as
1:2014cv04482 Defendant: Zoll Medical
Corporation Plaintiff: Derrick Laster Cause Of Action: Denial of
Overtime Compensation Court: Second Circuit › New
York › New York Southern District Court Type: Labor › Fair Labor
Standards Act ZOLL Medical Corporation v.
Cardiac Science Corporation Filed: June 23, 2014 as
3:2014mc00008 Defendant: Cardiac Science
Corporation Plaintiff: ZOLL Medical
Corporation Court: Seventh Circuit › Wisconsin
› Wisconsin Western District Court Type: Other Statutes › Other Zoll Medical Corporation v.
Philips Electronics North We have
downloadable decisions or orders for this case Filed: May 12, 2014 as 14-1467 Court: Federal Circuit U.S.
Court of Appeals, Federal Circuit Type: Intellectual Property ›
Patent Infringement (Fed. Question) |
|
|
|
|
TRADEMARKS |
SORENSEN MEDICAL SUCTION APPARATUS,
CARDIAC ARREST VEHICLES AND HEART-LUNG RESUSCITATORS Owned by: ZOLL MEDICAL
CORPORATION Serial Number: 72325281 LIFECOR CARDIAC ARRHYTHMIA DEVICES Owned by: ZOLL MEDICAL
CORPORATION Serial Number: 73666759 SMART ALARMS software and computer hardware
for assessment of cardiac status and providing advisory indications of same
for use in defibrillators… Owned by: ZOLL MEDICAL
CORPORATION Serial Number: 74413246 POWERCHARGER power component for
pacemaker/defibrillator Owned by: ZOLL MEDICAL
CORPORATION Serial Number: 74484498 WCD medical devices, namely
external cardioverters and defibrillators Owned by: ZOLL MEDICAL
CORPORATION Serial Number: 74679012 SMARTVIEW Software for reviewing
emergency medical incident, treatment and data analysis information on a
display device Owned by: ZOLL MEDICAL
CORPORATION Serial Number: 75705619 |
|
|
|
|
RENEWAL
HISTORY |
The name was changed
from: ZMI CORPORATION on 01-29-1992 The name was changed
from: ROSS RESEARCH, INC. on 02-02-1984 |
|
|
|
|
UCC
|
UCC-1 Standard UCC Filing Number: Filing Date: 201847002800 6/8/2018 7:53:00 AM Files: 201847002800_1.pdf,
1 pgs Action: InitialFiling Request Certified Copy Debtor(s) ZOLL MEDICAL CORPORATION 269 MILL ROAD CHELMSFORD MA 01824 Corp Type: CORPORATION Secured Parties U.S. BANK EQUIPMENT FINANCE 1310 MADRID STREET MARSHALL MN 56258 UCC-1 Standard UCC Filing Number: Filing Date: 201845052870 3/30/2018 7:04:00 AM Files: 201845052870_1.pdf,
1 pgs Action: InitialFiling Request Certified Copy Debtor(s) ZOLL MEDICAL CORPORATION 121 GAMMA DRIVE PITTSBURGH PA 15238 Corp Type: CORPORATION Secured Parties U.S. BANK EQUIPMENT FINANCE 1310 MADRID STREET MARSHALL MN 56258 UCC-1 Standard UCC Filing Number: Filing Date: 201740197810 10/2/2017 10:57:00 AM Files: 201740197810_1.pdf,
1 pgs Action: InitialFiling Request Certified Copy Debtor(s) ZOLL MEDICAL CORPORATION 121 GAMMA DRIVE PITTSBURGH PA 15238 Corp Type: CORPORATION Secured Parties U.S. BANK EQUIPMENT FINANCE, A
DIVISION OF U.S. BANK NATIONAL ASSOCIATION 1310 MADRID STREET MARSHALL MN 56258 UCC-1 Standard UCC Filing Number: Filing Date: 201736171880 4/19/2017 9:06:00 AM Files: 201736171880_1.pdf,
1 pgs Action: InitialFiling Request Certified Copy Debtor(s) ZOLL MEDICAL CORPORATION 269 MILL ROAD CHELMSFORD MA 01824 Corp Type: CORPORATION Secured Parties U.S. BANK EQUIPMENT FINANCE, A
DIVISION OF U.S. BANK NATIONAL ASSOCIATION 1310 MADRID STREET MARSHALL MN 56258 UCC-1 Standard UCC Filing Number: Filing Date: 201736088700 4/14/2017 8:10:00 AM Files: 201736088700_1.pdf,
1 pgs Action: InitialFiling Request Certified Copy Debtor(s) ZOLL MEDICAL CORPORATION 269 MILL ROAD CHELMSFORD MA 01824 Corp Type: CORPORATION Secured Parties U.S. BANK EQUIPMENT FINANCE 1310 MADRID STREET MARSHALL MN 56258 UCC-1 Standard UCC Filing Number: Filing Date: 201735653800 3/29/2017 8:54:00 AM Files: 201735653800_1.pdf,
1 pgs Action: InitialFiling Request Certified Copy Debtor(s) ZOLL MEDICAL CORPORATION 269 MILL ROAD CHELMSFORD MA 01824 Corp Type: CORPORATION Secured Parties U.S. BANK EQUIPMENT FINANCE 1310 MADRID STREET MARSHALL MN 56258 UCC-1 Standard UCC Filing Number: Filing Date: 201734500600 2/9/2017 8:56:00 AM Files: 201734500600_1.pdf,
1 pgs Action: InitialFiling Request Certified Copy Debtor(s) ZOLL MEDICAL CORPORATION 269 MILL ROAD CHELMSFORD MA 01824 Corp Type: CORPORATION Secured Parties U.S. BANK EQUIPMENT FINANCE 1310 MADRID STREET MARSHALL MN 56258 UCC-1 Standard UCC Filing Number: Filing Date: 201734500510 2/9/2017 8:56:00 AM Files: 201734500510_1.pdf,
1 pgs Action: InitialFiling Request Certified Copy Debtor(s) ZOLL MEDICAL CORPORATION 269 MILL ROAD CHELMSFORD MA 01824 Corp Type: CORPORATION Secured Parties U.S. BANK EQUIPMENT FINANCE 1310 MADRID STREET MARSHALL MN 56258 |
|
|
|
SUMMARY
|
|
|
|
Zoll Medical Corporation is a large-sized
organization in the electromedical equipment manufacturers industry located
in Chelmsford, MA. Its experience dates back to
1980 and now has an estimated $183M million in yearly estimated net assets
and 4000 employees. Japanese firm Asahi Kasei acquired
ZOLL in 2012. |
|
|
|
RISK
INFORMATION
|
|
|
DEBTS |
Controlled |
|
PAYMENTS |
Regular |
|
CASH
FLOW |
Normal |
|
STATUS |
Active |
|
|
|
INTERVIEW
|
|
|
NAME |
Sebastian |
|
POSITION |
Assistant |
|
COMMENTS |
He confirmed name, address,
experience, name, managers, state, and group. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 68.15 |
|
|
1 |
INR 90.27 |
|
Euro |
1 |
INR 79.35 |
|
US Dollar |
1 |
INR 68.18 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
VIV |
|
|
|
|
Report Prepared
by : |
TPT |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.